Enjoy complimentary customisation on priority with our Enterprise License!
The pleurodynia treatment market share is expected to increase to USD 24.61 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 4.76%.
This pleurodynia treatment market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers pleurodynia treatment market segmentation by therapy (painkillers and immunoglobulin) and geography (North America, Europe, Asia, and Rest of World (ROW)). The pleurodynia treatment market report also offers information on several market vendors, including Abbott Laboratories, GlaxoSmithKline Plc, Hudson Pharma, Johnson and Johnson, Merck and Co. Inc., Novartis AG, Opsonin Pharma Ltd., Pfizer Inc., Reckitt Benckiser Group PLC, and Sanofi among others.
Download the Free Report Sample to Unlock the Pleurodynia Treatment Market Size for the Forecast Period and Other Important Statistics
The growing prevalence of viral infections is notably driving the pleurodynia treatment market growth, although factors such as stringent regulatory guidelines may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the pleurodynia treatment industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Pleurodynia Treatment Market Driver
One of the key factors driving the global pleurodynia treatment market growth is the growing prevalence of viral infections. The diagnosis of pleurodynia is more common in older children and adults. The involvement of the abdominal muscles is more common in younger children than in older children and adults, who more often have thoracic pain. The major etiologic agents in epidemic pleurodynia are viruses Coxsackie B3 and B5. As per a cohort study of COVID-19-associated musculoskeletal symptoms conducted on 294 hospitalized COVID-19 patients in March 2021, 88 (30%) reported musculoskeletal complaints, and among these 88 patients, 37.5% had myalgia. Countries such as China and India are hyperendemic countries for viral infections. Therefore, the growing prevalence of pleurodynia disease will lead to pleurodynia treatment, which will the market growth during the forecast period.
Key Pleurodynia Treatment Market Trend
Growing partnerships is one of the key pleurodynia treatment market trends that is expected to impact the industry positively in the forecast period. For instance, in November 2021, the State of Qatar and the WHO announced a partnership and their commitment to work jointly in addressing global health challenges. Also, in June 2021, The US Department of Health and Human Services (HHS) announced a public-private partnership that enables investments from venture capital firms. Additionally, alliances between private manufacturers and public health agencies create public awareness about various diseases through different campaigns. For instance, GlaxoSmithKline plc. the public policy states its willingness to support and participate in research and funding of clinical trials for vaccines and antiviral drugs in pandemic situations. Such factors will further support the market growth in the coming years.
Key Pleurodynia Treatment Market Challenge
One of the key challenges to the global pleurodynia treatment market growth is the stringent regulatory guidelines. Safety, efficacy, pharmacological data, pharmacodynamic effects, and drug interactions are some of the key factors that are examined by these regulatory bodies. Thus, if a drug fails to meet even one of the criteria, it is expected to receive a complete response letter (CRL) or may face complete rejection from regulatory agencies. On receiving a complete response letter, a drug applicant is required to furnish additional data pertaining to the drug. This may require additional clinical trials, which can increase the R&D expenditure for the drug applicant. Such factors may limit the growth of the market in focus during the forecast period.
This pleurodynia treatment market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.
Technavio categorizes the global pleurodynia treatment market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the pleurodynia treatment market during the forecast period.
The report analyzes the market's competitive landscape and offers information on several market vendors, including:
This statistical study of the pleurodynia treatment market encompasses successful business strategies deployed by the key vendors. The pleurodynia treatment market is concentrated and the vendors are deploying growth strategies such as investment in R&D to compete in the market.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The pleurodynia treatment market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
Our report provides extensive information on the value chain analysis for the pleurodynia treatment market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
For more insights on the market share of various regions Request for a FREE sample now!
40% of the market's growth will originate from North America during the forecast period. US and Canada are the key markets for pleurodynia treatment in North America. Market growth in this region will be faster than the growth of the market in Rest of World (ROW).
The growing research on antiviral drugs, the increasing healthcare expenditure in the region, and the presence of key vendors will facilitate the pleurodynia treatment market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
COVID Impact and Recovery Analysis
The COVID-19 pandemic had a negative impact on the growth of the regional market in 2020-2021. However, the initiation of large-scale COVID-19 vaccination drives from December 2020 onwards and the subsequent lifting of lockdown restrictions led to the gradual resumption of operations at pharmaceutical manufacturing and logistics units, which helped in easing R&D-related constraints. Thus, the gradually improving situation from the impact of the COVID-19 pandemic in the region will increase the demand for pleurodynia treatment in North America during the forecast period.
To gain further insights on the market contribution of various segments Request for a FREE sample
The pleurodynia treatment market share growth by the painkillers segment will be significant during the forecast period. At present, there is no specific treatment for pleurodynia. However, non-steroidal anti-inflammatory drugs (NSAIDs) for pain and pleurisy (if present) or blockage of the peripheral nerves (e.g., the intercostal nerve) with 1% lidocaine (Xylocaine) infusion are prescribed for patients. For instance, Advil is used to relieve severe pain at the site. Thus, the adoption of painkillers to relieve the pain caused by pleurodynia due to infection by Coxsackie A and Coxsackie B viruses drives the growth of this segment and, in turn, the market in focus during the forecast period.
This report provides an accurate prediction of the contribution of all the segments to the growth of the pleurodynia treatment market size and actionable market insights on post COVID-19 impact on each segment.
Pleurodynia Treatment Market Scope |
|
Report Coverage |
Details |
Page number |
120 |
Base year |
2021 |
Forecast period |
2022-2026 |
Growth momentum & CAGR |
Accelerate at a CAGR of 4.76% |
Market growth 2022-2026 |
$ 24.61 million |
Market structure |
Concentrated |
YoY growth (%) |
2.96 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 40% |
Key consumer countries |
US, Canada, Denmark, Norway, China, US, Canada, Denmark, Norway, and China |
Competitive landscape |
Leading companies, Competitive strategies, Consumer engagement scope |
Key companies profiled |
Abbott Laboratories, GlaxoSmithKline Plc, Hudson Pharma, Johnson and Johnson, Merck and Co. Inc., Novartis AG, Opsonin Pharma Ltd., Pfizer Inc., Reckitt Benckiser Group PLC, and Sanofi |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by Therapy
6 Customer Landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
9 Vendor Landscape
10 Vendor Analysis
11 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.